On Monday Qiagen reiterated its preliminary 2019 earnings figures and addressed an investor's wrath, while Guardant Health highlighted its cancer testing plans.
A federal court said Guardant CEO Helmy Eltoukhy deleted emails pertaining to two similar cases, but it remains unclear whether he did so intentionally.
The researchers used the Guardant360 assay and droplet digital PCR to identify genetic mutations in circulating tumor DNA that had been shed into the patients' bloodstream.
Industry experts say a receptive market and investor interest in new technologies have spurred the increase in genomics tools and molecular diagnostics IPOs.
